- Home
- CCEC vs RLAY Comparison
CCEC vs RLAY Comparison
Compare CCEC & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CCEC | RLAY |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2007 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CCEC | RLAY |
|---|---|---|
| Price | $21.31 | $8.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $25.67 | $16.00 |
| AVG Volume (30 Days) | 7.4K | ★ 2.2M |
| Earning Date | 02-05-2026 | 11-06-2025 |
| Dividend Yield | ★ 2.82% | N/A |
| EPS Growth | ★ 304.00 | N/A |
| EPS | ★ 4.79 | N/A |
| Revenue | ★ $421,795,000.00 | $8,355,000.00 |
| Revenue This Year | $14.32 | $20.47 |
| Revenue Next Year | $12.68 | N/A |
| P/E Ratio | $8.29 | ★ N/A |
| Revenue Growth | ★ 32.74 | N/A |
| 52 Week Low | $14.09 | $1.78 |
| 52 Week High | $24.83 | $9.04 |
Technical Indicators
Market Signals| Indicator | CCEC | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 55.62 | 63.56 |
| Support Level | $20.23 | $8.13 |
| Resistance Level | $21.46 | $8.76 |
| Average True Range (ATR) | 0.76 | 0.49 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 88.96 | 73.77 |
Price Performance
Historical ComparisonAbout CCEC Capital Clean Energy Carriers Corp.
Capital Clean Energy Carriers Corp is an international shipping company. It is the platform of gas carriage solutions with a focus on the energy transition. The company owns 20 high-specification vessels, including 12 latest-generation LNG carriers (LNG/Cs) and eight legacy Neo-Panamax container vessels.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).